Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.48 |
| ▸ | ACSS2 | Q9NR19 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559474 | 1.00 | TLR7 (0.48) | TLR7ACSS2KDM4EALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL20266404 | 0.99 | TLR7 (0.47) | TLR7ACSS2KDM4EALDH1A1PKM | |
| SCHEMBL23287291 | 0.89 | ACSS2 (0.51) | TLR7ACSS2KDM4EALDH1A1PKM | |
| SCHEMBL27478591 | 0.87 | ACSS2 (0.45) | TLR7ACSS2KDM4EALDH1A1PKM | |
| SCHEMBL25767043 | 0.86 | ACSS2 (0.46) | TLR7ACSS2KDM4EALDH1A1PKM | |
| SCHEMBL24265281 | 0.85 | ACSS2 (0.49) | ACSS2KDM4EALDH1A1PKMHTT | |
| SCHEMBL30676114 | 0.84 | ACSS2 (0.46) | ACSS2KDM4EHTTDRD2TBXA2R | |
| SCHEMBL20266433 | 0.84 | ACSS2 (0.46) | ACSS2KDM4EHTTDRD2TBXA2R | |
| SCHEMBL31413142 | 0.82 | ACSS2 (0.49) | ACSS2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL30474209 | 0.82 | TLR7 (0.48) | TLR7ACSS2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250099431-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4219487-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4523751-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250084072-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-13 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109607-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | TLR7 614/4885ACSS2 1602/4885KDM4E 1059/4885 |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | TLR7 699/4885ACSS2 1613/4885KDM4E 1142/4885 |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | TLR7 699/4885ACSS2 1613/4885KDM4E 1142/4885 |
| US-20250099431-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | TLR7 1733/4885ACSS2 1301/4885KDM4E 2208/4885 |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | TLR7 699/4885ACSS2 1613/4885KDM4E 1142/4885 |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | TLR7 939/4885ACSS2 1630/4885KDM4E 791/4885 |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | TLR7 699/4885ACSS2 1613/4885KDM4E 1142/4885 |
| US-20250084072-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | TLR7 1879/4885ACSS2 1300/4885KDM4E 2322/4885 |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | TLR7 614/4885ACSS2 1602/4885KDM4E 1059/4885 |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | TLR7 614/4885ACSS2 1602/4885KDM4E 1059/4885 |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | TLR7 699/4885ACSS2 1613/4885KDM4E 1142/4885 |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | TLR7 699/4885ACSS2 1613/4885KDM4E 1142/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | TLR7 1526/4885ACSS2 354/4885KDM4E 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.